New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:24 EDTPETX, ZTSJefferies to hold a conference
Animal Health Day is being held in New York on March 27.
News For ZTS;PETX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
08:29 EDTPETXAratana Therapeutics' AT-016 meets endpoint in dose confirmation study
Aratana Therapeutics' strategic partner VetStem Biopharma has shared positive results from a dose confirmation study of AT-016, an adipose-derived allogeneic stem cell product exclusively licensed to Aratana for the treatment of osteoarthritis pain in dogs. The double-blinded, multi-site, placebo-controlled field efficacy trial enrolled approximately 90 dogs with osteoarthritis. The dogs who received a single intra-articular injection of AT-016 demonstrated a statistically significant improvement in treatment versus placebo. The primary endpoint was treatment success based on the Client Specific Outcome Measurement on day 60. Based on current timelines, the final study report is being prepared for FDA submission and agreement on the pivotal field effectiveness study design. If approved by the FDA's Center for Veterinary Medicine, AT-016 could be commercially available in late-2017 or 2018.
July 29, 2015
10:00 EDTPETXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:47 EDTPETXAratana Therapeutics initiated with a Buy at Lake Street
Target $28.
July 27, 2015
07:18 EDTPETXAratana Therapeutics reports cats weight changes in AT-002 study
Subscribe for More Information
July 22, 2015
09:25 EDTPETXAratana Therapeutics updates canine monoclonal antibody product pipeline
Aratana Therapeutics provided an update on the development, manufacturing and commercialization of their monoclonal antibodies targeting canine B-cell lymphoma and canine T-cell lymphoma. AT-004 has received full licensure from the United States Department of Agriculture, and AT-005 has received conditional licensure from the USDA and Aratana continues to anticipate full licensure in 2015. Aratana has completed enrollment in its second designed to assess adding AT-005 to a multi-agent chemotherapy protocol for dogs with T-cell lymphoma. Results from two studies are expected by mid-2016. Aratana continues to make AT-005 commercially available through a T-cell Clinical Experience Program. Aratana expects to report the initial results of B-CEP and the mini B-CHOMP study results in mid-2016. Aratana anticipates that it will remain manufacturing constrained on AT-004 until late-2016. Aratana expects a limited commercialization through the T-CEP and B-CEP programs until late 2016 at which time a full commercial launch is anticipated.
July 21, 2015
16:25 EDTZTSZoetis files automatic mixed securities shelf
Subscribe for More Information
06:58 EDTZTSZoetis added to US 1 List at BofA/Merrill
July 20, 2015
08:38 EDTZTSAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:30 EDTZTSZoetis 'highly likely' to merge with Bayer unit in 2016, says Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use